Alle Storys
Folgen
Keine Story von curasan AG mehr verpassen.

curasan AG

curasan AG: REVOIS® All-in-One Dental Implant System Registered in the U.S.

Kleinostheim (euro adhoc) -

  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
new product
curasan AG, a German leader in
regenerative medicine, has obtained FDA clearance for its REVOIS® 
All-in-One dental implant system, permitting the sale of the system 
in the U.S. This means that the system can be rolled out earlier than
originally planned - the rollout will take place at the ICOI World 
Congress in San Francisco in late August 2007.
REVOIS® gives curasan direct access to the dental implant market, the
segment within dental surgery that generates the highest revenues and
earnings. Curasan Inc., the company´s U.S. sales organization, has 
already been very successful in that country with its Cerasorb® 
synthetic bone substitute and its Epi-Guide® resorbable membrane. The
excellent rapport with the target group, dental implantologists, and 
with opinion leaders that the company has established with these 
products are an excellent basis for marketing the REVOIS® All-in-One 
dental implant system.
"This step represents another important milestone in the 
implementation of our corporate strategy," said curasan´s CEO Hans 
Dieter Rössler. "This strategy calls on us to organize our sales and 
marketing activities with a clear focus on the dental market. Of 
course, our R&D department will continue to develop new products for 
use in orthopedics, for skin transplants and for other fields. These 
will be marketed by way of license agreements and by cooperation with
multinational groups."
A Truly Useful Innovation: REVOIS® - the REVOlutionary Implant System
- is an intelligent modular system that achieves maximum precision 
with a minimum number of parts, covering all implantological 
requirements with only 120 components. This simplifies procurement, 
allows the reduction of expensive inventory, and greatly enhances the
component selection process in actual clinical practice.
One pivotal element is the multi-functional precision abutment. It 
fits all implant diameters and enables the user work with only one 
prosthetic line.
The REVOIS All-in-One System was designed for clinicians who demand 
highest quality and want to safely cover all implantological 
requirements with a single system but who, nevertheless, value 
simplicity of use and economical procedures as well as excellent 
precision and esthetics. Implantologists, prosthodontists and dental 
technicians can benefit from considerable savings in time and costs.
end of announcement                               euro adhoc 14.06.2007 09:26:04

Further inquiry note:

Kerstin Kornett
Vorstandsassistentin
Telefon: +49(0)6027 4686-431
E-Mail: kerstin.kornett@curasan.de

Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime
standard
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade

Weitere Storys: curasan AG
Weitere Storys: curasan AG